Merit Medical(US:MMSI)2026-01-08 21:33Revenue Performance - Merit Medical reported preliminary unaudited revenue for Q4 2025 in the range of approximately $389 million to $395 million, representing an increase of approximately 10% to 11% year-over-year[9]. - Preliminary unaudited constant currency revenue for Q4 2025 increased by approximately 8% to 10% year-over-year[9]. - The impact of foreign exchange on preliminary revenue was approximately $(4.4) million for the three-month period ended December 31, 2025[13]. - Merit Medical's preliminary unaudited revenue information should not be regarded as a reliable prediction of actual future results[23]. Financial Guidance and Reporting - The company plans to announce its financial results for the year ended December 31, 2025, and issue fiscal year 2026 guidance on February 24, 2026[7]. - Merit Medical's management emphasizes the importance of non-GAAP financial measures, such as constant currency revenue, for evaluating business trends and performance[10]. Strategic Initiatives - Merit Medical's Continued Growth Initiatives aim to achieve related financial targets for the three-year period ending December 31, 2026[5]. - Merit Medical is focused on integrating the C2 CryoBalloon device and related assets acquired from Pentax of America, Inc. in November 2025[19]. Leadership and Workforce - The company has undergone a leadership transition, with F. Ann Millner appointed as Chair of the Board effective January 5, 2026[1]. - Merit Medical employs approximately 7,500 people worldwide and serves customers globally with a sales force and clinical support team of over 800 individuals[17].